1 to 9 of 19 results

Boehringer Ingelheim enters research pact with Yale University

Boehringer Ingelheim enters research pact with Yale University


German family-owned pharma major Boehringer Ingelheim has entered into a collaboration with Yale University,…

Boehringer IngelheimGermanyImmunologicalsOncologyPharmaceuticalResearchRespiratory and Pulmonary

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates


Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

Stallergenes and DBV Technologies collaborate in birch pollen allergy research


French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014


Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product


US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

Ares Life Sciences to acquire Albion Medical and its GREER Laboratories unit


Ares Life Sciences says it has signed a definitive agreement to acquire 100% of the share capital of…

Albion MedicalAres Life SciencesGREER LaboratoriesImmunologicalsMergers & AcquisitionsOralairPharmaceuticalRespiratory and PulmonaryStallergenes

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval


The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

1 to 9 of 19 results



Back to top